STOCK TITAN

Monte Rosa Therapeutics: T. Rowe Price reports 8.6% stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Monte Rosa Therapeutics, Inc. was the subject of Amendment No. 8, in which T. Rowe Price Associates, Inc. reported 7,356,865 common shares, or 8.6% of the class, as beneficially owned. T. Rowe Price reported sole voting power over 7,349,108 shares and sole dispositive power over 7,356,865 shares, while expressly denying that the report was an admission that it is the beneficial owner. Vice President Ellen York signed the statement.

Reported beneficial ownership 7,356,865 shares Reported by T. Rowe Price Associates, Inc.; it expressly denied that the report was an admission of beneficial ownership.
Reported percentage of class 8.6% T. Rowe Price Associates, Inc.'s reported position.
Sole voting power 7,349,108 shares Reported by T. Rowe Price Associates, Inc.
Sole dispositive power 7,356,865 shares Reported by T. Rowe Price Associates, Inc.
Shared voting power 0 shares Reported by T. Rowe Price Associates, Inc.
Shared dispositive power 0 shares Reported by T. Rowe Price Associates, Inc.
beneficial ownership regulatory
"beneficial ownership is expressly denied"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Sole Voting Power regulatory
"Sole Voting Power 7,349,108.00"
Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.
Sole Dispositive Power regulatory
"Sole Dispositive Power 7,356,865.00"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many GLUE shares did T. Rowe Price Associates report owning?

T. Rowe Price Associates, Inc. reported 7,356,865 Monte Rosa common shares, equal to 8.6% of the class. It reported sole voting power over 7,349,108 shares and sole dispositive power over 7,356,865 shares, while expressly denying that the report was an admission of beneficial ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





61225M102

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G



T. Rowe Price Associates, Inc.
Signature:Ellen York
Name/Title:Vice President
Date:11/16/2026

Keep reading